A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.
ABSTRACT Patients were less tolerant of CBD-rich botanical extract compared with placebo, taking on average one-third fewer capsules, and having more compliance-related protocol deviations (principally insufficient exposure), prompting identification of a per protocol (PP) analysis set. The primary endpoint was negative;
ABSTRACT These studies show different levels of elements of the ECS in murine and human IBD models. Further delineation of mechanism of action is needed to determine whether these results are pathologic or reactive effects to inflammation. However, cannabinoids appear to
ABSTRACT Experimental evidence gathered from preclinical IBD models and conducted in rodents point to a strong potential of the ECS components to serve as drug targets in inflammatory diseases of the intestine. Data suggest a homeostatic role of the ECS in
ABSTRACT Cannabinoids have been shown to regulate the tissue response to excessive inflammation in the colon, mediated by both dampening smooth-muscular irritation caused by inflammation and suppressing proinflammatory cytokines, thus controlling the cellular pathways leading to inflammatory responses. These results strongly